Roivant reported that mosliciguat achieved the primary endpoint in a 16-week Phase 2 study of a pulmonary hypertension population, posting a statistically significant 56% reduction in pulmonary vascular resistance versus placebo. The company also said multiple secondary endpoints met statistical significance. Roivant cited a 35-meter placebo-adjusted improvement in six-minute walk distance and a 53% placebo-adjusted reduction in NT-proBNP, pointing to both functional and biomarker signal strength. The data add a key de-risking step for a therapy that Roivant previously acquired from Bayer. The result strengthens Roivant’s pipeline narrative ahead of later-stage work and provides a near-term financial catalyst by demonstrating efficacy signal alignment in a disease area where differentiation depends on measurable hemodynamic effects. The readout also reinforces investors’ preference for assets showing both physiologic and clinical performance metrics.